New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT03843359
First seen Jan 10, 2026 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This early-phase study tests a new experimental drug (GSK3745417) alone or combined with another drug (dostarlimab) in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a first step to see if the drug might help control these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Houston, Texas, 77030, United States
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Toronto, Ontario, M5G 1Z9, Canada
-
GSK Investigational Site
Bordeaux, 33076, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Tokyo, 135-8550, Japan
-
GSK Investigational Site
Amsterdam, 1066 CX, Netherlands
-
GSK Investigational Site
Amsterdam, 1081 HV, Netherlands
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.